Skip to main content
Premium Trial:

Request an Annual Quote

At Least They're Not Reading 'Sys Bio for Dummies'

Derek Lowe blogs about scientists reading business books, and what's so very wrong about that, in his opinion. "To be honest, I've always had a bit of a nervous feeling about anyone in the sciences who really seems to enjoy pop business books," he writes at In the Pipeline. "Most of the big sellers seem to be full of post hoc reasoning, sweeping statements that are backed up by weak or nonexistent evidence, and plenty of blatant padding." Whether scientists and business people will ever get along is questionable, but readers offer their two cents (in the comments) on who is most clueless when it comes to making science and business mesh.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.